Insulinoma laboratory tests: Difference between revisions

	Insulinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Insulinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
X-ray
Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Insulinoma laboratory tests On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Insulinoma laboratory tests All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Insulinoma laboratory tests
CDC on Insulinoma laboratory tests
Insulinoma laboratory tests in the news
Blogs on Insulinoma laboratory tests
Directions to Hospitals Treating Insulinoma
Risk calculators and risk factors for Insulinoma laboratory tests

VisualWikitext

Revision as of 22:11, 10 August 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].

OR

Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

OR

[Test] is usually normal among patients with [disease name].

OR

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

OR

There are no diagnostic laboratory findings associated with [disease name].

Laboratory Findings

There are no diagnostic laboratory findings associated with [disease name].

OR

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
[Test] is usually normal among patients with [disease name].
Laboratory findings consistent with the diagnosis of [disease name] include
- [abnormal test 1]
- [abnormal test 2]
- [abnormal test 3]

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

References

Template:WH Template:WS

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Insulinoma}}
-{{CMG}}{{AE}}{{PSD}}
+{{CMG}}; {{AE}} {{PSD}}
 ==Overview==
-Laboratory findings consistent with the diagnosis of insulinoma include 72 hour suppression test and [[Whipple's triad]].<ref name="pmid23430217">{{cite journal| author=Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y et al.| title=Diagnosis and management of insulinoma. | journal=World J Gastroenterol | year= 2013 | volume= 19 | issue= 6 | pages= 829-37 | pmid=23430217 | doi=10.3748/wjg.v19.i6.829 | pmc=PMC3574879 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23430217  }} </ref>
+An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
+OR
+Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
+OR
+[Test] is usually normal among patients with [disease name].
+OR
+Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
+OR
+There are no diagnostic laboratory findings associated with [disease name].
+==Laboratory Findings==
-==Laboratory Tests==
+*There are no diagnostic laboratory findings associated with [disease name].
-Laboratory findings consistent with the diagnosis of insulinoma include:<ref name="pmid23430217">{{cite journal| author=Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y et al.| title=Diagnosis and management of insulinoma. | journal=World J Gastroenterol | year= 2013 | volume= 19 | issue= 6 | pages= 829-37 | pmid=23430217 | doi=10.3748/wjg.v19.i6.829 | pmc=PMC3574879 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23430217  }} </ref>
+OR
-===Whipple's Triad===
+*An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
-The diagnosis of insulinoma is suspected in a patient with symptomatic fasting [[hypoglycemia]]. The conditions of [[Whipple’s triad]] that need to be met for the diagnosis of insulinoma are:<ref name="pmid23430217">{{cite journal| author=Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y et al.| title=Diagnosis and management of insulinoma. | journal=World J Gastroenterol | year= 2013 | volume= 19 | issue= 6 | pages= 829-37 | pmid=23430217 | doi=10.3748/wjg.v19.i6.829 | pmc=PMC3574879 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23430217  }} </ref>
+*[Test] is usually normal among patients with [disease name].
-:1. [[Hypoglycemia]] (plasma glucose < 50 mg/dL)
+*Laboratory findings consistent with the diagnosis of [disease name] include
-:2. Neuroglycopenic symptoms
+**[abnormal test 1]
-:3. Reversibility of symptoms with administration of [[glucose]]
+**[abnormal test 2]
+**[abnormal test 3]
-===Suppression Tests===
+*Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
-The gold standard blood tests needed to diagnose insulinoma during a 72 hour fast are:<ref name="pmid23430217">{{cite journal| author=Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y et al.| title=Diagnosis and management of insulinoma. | journal=World J Gastroenterol | year= 2013 | volume= 19 | issue= 6 | pages= 829-37 | pmid=23430217 | doi=10.3748/wjg.v19.i6.829 | pmc=PMC3574879 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23430217  }} </ref>
-*Plasma [[glucose]] level
-*[[Insulin]]
-*[[C-peptide]]
-*Pro-insulin
-The sensitivity of combination of these 4 tests after 72 hour fasting is around 99%.
-Normally, endogenous insulin production is suppressed in the setting of hypoglycemia.  A 72-hour fast, usually supervised in a hospital setting, can be done to see if insulin levels fail to suppress, which is a strong indicator of the presence of an insulin-secreting tumor.
-During the test, the patient may have calorie-free and caffeine-free liquids.  Capillary blood glucose is measured every 4 hours using a [[glucose meter|reflectance meter]], until values < 60 mg/dL (3.3 mmol/L) are obtained. Then, the frequency of blood glucose measurement is increased to every hour until values are < 49 mg/dL (2.7 mmol/L).  At that point, or when the patient has symptoms of hypoglycemia, a blood test is drawn for serum [[glucose]], [[insulin]], [[proinsulin]], and C-peptide levels.  The fast is stopped at that point, and the [[hypoglycemia]] is treated with intravenous [[dextrose]] or calorie-containing food or drink.<ref>Insulinoma. Wikipedia. https://en.wikipedia.org/wiki/Insulinoma</ref>
 ==References==
 {{Reflist|2}}
-[[Category:Disease]]
-[[Category:Endocrinology]]
-[[Category:Mature chapter]]
-{{WikiDoc Help Menu}}
+{{WH}}
-{{WikiDoc Sources}}
+{{WS}}

Insulinoma laboratory tests: Difference between revisions

Revision as of 22:11, 10 August 2017

Overview

Laboratory Findings

References

Navigation menu